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We evaluated the accuracy of a point-of-care test designed to measure adherence to isoniazid
(INH) preventive therapy in a hospital setting in Rio de Janeiro, Brazil. Patients on treatment
with daily INH and patients not receiving INH were included. Sensitivity and specificity of the
test were 84%/98% at the first minute, and 95%/98% at the fifth minute, respectively. Among
smokers, sensitivity and specificity was reduced (80%/89% at the fifth minute, respectively),
but only 17% smoked. This test accurately detected INH metabolites 24 h following directly
observed INH intake, though sensitivity and specificity may be compromised by tobacco smoke
exposure.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Treatment of latent tuberculosis (TB) infection with isoni-
azid (INH) preventive therapy (IPT) as a TB control strategy
has been limited predominantly to developed countries,
though in settings with high rates of HIV co-infection, this
strategy is being re-visited.1 Ensuring adherence to IPT isis Clinical Research Laboratory,
Janeiro, Rua Professor Rodolpho P
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rj.br (R.L. Guerra).
0 Elsevier Ltd. All rights reserveda significant challenge. Although measuring patient adher-
ence is essential, it is often limited to patient report.2
The Arkansas color method of detecting INH metabo-
lites in the urine relies on a colorimetric assay test
performed in a laboratory.3e6 A recently developed test,
IsoScreen (GFC Diagnostics Limited, Oxfordshire, UK),
utilizes the reagents of the Arkansas method in a patentedInstitute of Thoracic Diseases, Clementino Fraga Filho University
aulo Rocco, No. 255, 6 andar, Cidade Universita´ria, Rio de Janeiro,
853.
.
Testing adherence to treatment with INH 755plastic testing device (SafeTube), allowing test evaluation
in the field. However, IsoScreen has only been tested in
small groups of patients.7
The objective of this study was to determine, under
routine conditions, the sensitivity and specificity of the
IsoScreen test in measuring adherence to IPT among an out-
patient hospital population with high prevalence of TB in
Rio de Janeiro, Brazil.
Methods
We recruited two patient groups: patients currently on
treatment with daily INH were classified as the INH group;
and individuals attending the hospital for initial evaluation
for active or latent TB therapy initiation were considered
the control group. For the INH group, a first visit was
a routinely scheduled appointment in which the subjects
took INH under supervision, and a second visit was sched-
uled after 24 h for urine specimen collection. The control
group had only one visit to provide the urine specimen. All
patients were 18 years. Exclusion criteria were non-daily
INH use for the INH group, and INH intake within the last 30
days for the controls. Urine specimens were aspirated using
the syringe connected to the device, then injected into the
dried chemicals within the device and shaken. The urine
color was recorded 1 and 5 min after mixing. The test was
considered positive when urine turned green or dark blue
and negative if no change in color. The McNemar test was
used to analyze the difference between test sensitivities at
first and fifth minutes.
This project was approved by the Clementino Fraga Filho
University Hospital and the Johns Hopkins School of Medi-
cine institutional review boards.
Results
From June 2007 to July 2008, a total of 146 subjects were
included in the study. Two patients were excluded from the
INH group because they did not return to provide a urine
specimen. There were 94 patients in the INH group and 50
in the control group.
In the INH group, 65 (69%) patients were on IPT while 29
(31%) were on active TB treatment. The median time from
INH ingestion and test performance was 23.4 h (IQR: 23.0e
24.2 h). Table 1 shows test accuracy. Sensitivity was 10.3%
greater at the fifth minute (94.7%) versus the first minute
(84.4%; p< 0.01), and specificity was 98% at both readings.Table 1 Isoscreen test accuracy at 1 and 5 min after test perfo
Color 1st Minute
INH group Control group Sensitivity
(95% CI)
Specificity
(95% CI)
Yellow 14 49
Green 8 0
Blue 68 1 84.4%a 98.0%
Missing 4 0 (78.5e90.3) (95.7e100
Total 94 50
Sensitivity/specificity calculated with blue and green reflecting a pos
a The difference between sensitivity at fifth and first minutes was 1The difference between sensitivities at first and fifth
minutes was due to nine specimens that became blue after
the first minute. Table 2 shows demographic characteristics
of individuals with false test results. Among smokers, the
sensitivity and specificity decreased to 80% and 88.8% at
fifth minute, respectively, though only 17% (24/144) were
smokers.
Discussion
We evaluated a point-of-care test for measuring adherence
to IPT, and our findings show high sensitivity and specificity
(95%) with mean time from INH ingestion and test results
of approximately 24 h. Based on these results, this test is
being utilized in the THRio study in Rio de Janeiro, Brazil
investigating the adherence of HIV-infected patients
receiving IPT.8
Adherence to IPT has been reported to be enhanced by
measures such as provision of incentives and treatment
supervision.2,9 However, due to the high number of patients
who would be recommended to receive IPT, these measures
are prohibitively expensive, especially in developing coun-
tries where the limited resources available are directed
towards detection and treatment of active disease. The
IsoScreen test might be a practical alternative for this
purpose since it can be performed without strict laboratory
conditions and provides an immediate confirmation of
patient compliance. In a previous study, non-adherence to
IPT was found in 28.5% of patients submitted to the
Arkansas method. However, 83% of patients who were
tested negative at the first visit became adherent in the
second visit, suggesting that biological acknowledgement of
their non-adherence may have changed their behavior.6
In our study, in five patients for whom INH ingestion was
confirmed, the test was negative. Four of them were on
regular treatment with other drugs, although none were
receiving the same drugs. Although we did not assess ace-
tylator status, the false-negative results could be due to
faster drug metabolization, as previously reported, or it may
actually reflect variability in INH metabolites detected in
urine or inherent test inaccuracy.10,11 Test accuracy may also
have been compromised by tobacco smoke exposure simi-
larly to another study evaluating the test spectrophoto-
metrically. In that study, while the urine of non-smokers
taking INH turned deep blue, the presence of nicotine and its
metabolites in urine of smokers taking INH produced a green
color after reaction, resulting in the blue-green color.3rmance.
5th Minute
INH group Control group Sensitivity
(95% CI)
Specificity
(95% CI)
5 49
8 0
81 1 94.7a 98.0
) 0 0 (91.0e98.4) (95.7e100)
94 50
itive result.
0.3% (p< 0.01).
Table 2 Demographic characteristics of patients with false test results at 1 and 5 min after test performance.
Total Age Gender male Race white Smoker Use of other medicationsa
Mean (SD) n (%) n (%) n (%) n (%)
Urine color at 1st minute
INH group
Yellow (false-negative) 14 45 (10.3) 9 (64) 5 (36) 3 (21) 6 (43)
Control group
Green (false-positive) 0 0 0 0 0 0
Blue (false-positive) 1 28 1 (100) 0 1 (100) 0
Urine color at 5th minute
INH group
Yellow (false-negative) 5 50 (5.3) 3 (60) 2 (40) 3 (60) 4 (80)
Control group
Green (false-positive) 0 0 0 0 0 0
Blue (false-positive) 1 28 1 (100) 0 1 (100) 0
a Regular medication use other than TB drugs.
756 R.L. Guerra et al.A limitation of our study is that it was unblinded. Since
the study was conducted under routine operational condi-
tions, the responsible nurse was aware of which subjects
were under current INH treatment and which subjects were
being investigated for TB (controls). Because a green color
(also considered as positive in this study) may not defini-
tively represent a positive result, we presented the results
stratified by color (Table 1). If green was not considered to
be a positive result, then sensitivity at 5 min would have
been 86%, while specificity would have remained
unchanged. We are confident that our technician was
readily able to differentiate between yellow and green,
and that the high sensitivity reported (95%) suggests strong
utility for this test in operational settings. Another limita-
tion is that the test accuracy was only measured within 24 h
of drug intake, thus we cannot confidently extrapolate our
results beyond this period of time. In programmatic
settings, patients may miss a dose 24 h prior to providing
a urine specimen, but may still be strongly adherent to
their regimen or take IPT the day before the urine test
simply to ‘‘appear’’ to be adherent. Thus, appropriate
counseling for test objective and an oral history of adher-
ence should always be included when using a biological
assay for measuring adherence.
In conclusion, the IsoScreen test accurately detected
INH metabolites 24 h following directly observed INH
intake. As an objective test, it might be used repeatedly as
a follow-up method to better characterize adherence and
potentially increase adherence among patients receiving
IPT or treatment for active TB.Acknowledgements
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